Kovo Health Tech - Senior VP of Finance, Mark Detz
Senior VP of Finance, Mark Detz
Source: Newsfile Corp.
  • Kovo HealthTech (KOVO) has appointed Mark Detz, CPA, CA as Senior Vice President of Finance
  • Mark previously held several senior positions with Anheuser-Busch and holds an undergraduate degree from the Schulich School of Business
  • Kovo HealthTech is a growing healthcare technology company that specializes in billing-as-a-service
  • Kovo HealthTech Corporation (KOVO) opened trading at C$0.39 per share

Kovo HealthTech (KOVO) has appointed veteran finance expert Mark Detz, CPA, CA as its Senior Vice President of Finance.

Before joining Kovo, Detz held several senior positions with Anheuser-Busch, where he focused on strategy and financial operations, including financial reporting, forecasting, budgeting, mergers and acquisitions. Detz began his career as an auditor at KPMG and holds an undergraduate degree from the Schulich School of Business.

“As we look to continue to scale our business operations in 2022 through strategic acquisitions and organic growth, we’re excited to welcome Mark to the Kovo team,” says Kovo CFO Inder Saini.

“Mark’s entrepreneurial, disciplined approach and track-record with world-leading innovators like Anheuser-Busch and KPMG, will be instrumental in driving Kovo’s aggressive 2022 growth strategy,” he explains.

Kovo HealthTech is a growing healthcare technology company that specializes in billing-as-a-service.

The company helps healthcare providers seamlessly digitally track and manage complex patient care registration, services, billing, and payments using its proprietary OneRev technology platform.

Kovo HealthTech Corporation (KOVO) opened trading at C$0.39 per share.

More From The Market Online

Liberty Defense expands its international customer base

Liberty Defense Holdings (TSXV:SCAN), a provider of artificial intelligence technologies, expands its international customer base.

Unsung profits: Three microcap stocks with a strong case for value

A key factor behind picking winning microcap value stocks is identifying dislocations between company performance and market perception.

Theralase advances cancer research after private placement

Theralase Technologies (TSXV:TLT) closes a non-brokered private placement offering of 4.1 million shares for gross proceeds of C$750,200.